Description

TICASMART 90MG

Indications

TICASMART 90MG is primarily indicated for the treatment of patients with acute coronary syndrome (ACS), including those with unstable angina and non-ST elevation myocardial infarction (NSTEMI). It is also used in patients undergoing percutaneous coronary intervention (PCI) to reduce the risk of thrombotic events. The medication is designed to improve patient outcomes by preventing platelet aggregation, thereby reducing the likelihood of cardiovascular events.

Mechanism of Action

The active ingredient in TICASMART 90MG is ticagrelor, a potent oral antiplatelet agent that belongs to the class of cyclopentyltriazolopyrimidines. Ticagrelor functions by reversibly inhibiting the P2Y12 receptor on platelets, which is crucial for platelet activation and aggregation. By blocking this receptor, ticagrelor effectively reduces the formation of blood clots, thereby lowering the risk of myocardial infarction and other cardiovascular complications in patients with ACS.

Pharmacological Properties

TICASMART 90MG exhibits rapid absorption following oral administration, with peak plasma concentrations typically reached within 1 to 3 hours. The drug has a bioavailability of approximately 36%, which can be influenced by food intake. Ticagrelor is extensively metabolized in the liver, primarily by cytochrome P450 enzymes, particularly CYP3A4 and CYP3A5. The elimination half-life of ticagrelor is approximately 7 hours, and its metabolites are primarily excreted via the feces.

Contraindications

TICASMART 90MG is contraindicated in patients with a known hypersensitivity to ticagrelor or any of its components. It should not be used in patients with active bleeding, such as peptic ulcer disease or intracranial hemorrhage. Additionally, the drug is contraindicated in patients with severe hepatic impairment, as this may lead to increased plasma concentrations and a heightened risk of adverse effects.

Side Effects

Common side effects associated with TICASMART 90MG include bleeding complications, such as bruising, nosebleeds, and gastrointestinal bleeding. Other potential side effects may include dyspnea, headache, dizziness, and nausea. Serious adverse effects, although less common, can include life-threatening bleeding events and severe allergic reactions. Patients should be monitored closely for signs of bleeding and other serious side effects during treatment.

Dosage and Administration

The recommended dosage of TICASMART 90MG for adults is 90 mg taken twice daily, typically in conjunction with aspirin therapy (81 mg to 325 mg daily). It is important to initiate treatment with a loading dose of 180 mg on the first day to achieve rapid antiplatelet effects. The medication can be taken with or without food; however, consistency in administration with regard to meals is advised to maintain stable drug levels. Patients should be instructed to adhere strictly to the prescribed dosage to optimize therapeutic outcomes.

Interactions

TICASMART 90MG may interact with several medications, which can influence its efficacy and safety. Notably, strong inhibitors of CYP3A4, such as ketoconazole and clarithromycin, can increase plasma levels of ticagrelor, potentially leading to an increased risk of bleeding. Conversely, strong inducers of CYP3A4, such as rifampicin and St. John’s Wort, may reduce the effectiveness of ticagrelor by decreasing its plasma concentration. Patients should inform their healthcare providers of all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Prior to initiating treatment with TICASMART 90MG, healthcare providers should assess patients for any history of bleeding disorders, recent surgery, or any condition that may predispose them to bleeding. Caution is advised in patients with a history of respiratory issues, as ticagrelor has been associated with dyspnea in some individuals. Regular monitoring of hemoglobin and hematocrit levels is recommended to detect any signs of bleeding early. Additionally, patients should be educated on the signs and symptoms of bleeding and advised to seek immediate medical attention if they experience unusual bruising, prolonged bleeding, or any other concerning symptoms.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of TICASMART 90MG in reducing major cardiovascular events in patients with ACS. The pivotal study, the PLATO (Platelet Inhibition and Patient Outcomes) trial, showed that ticagrelor significantly reduced the rate of cardiovascular death, myocardial infarction, and stroke compared to clopidogrel. Furthermore, the trial indicated that ticagrelor was associated with a higher incidence of major bleeding events; however, the overall benefits in reducing thrombotic events outweighed the risks. Subsequent analyses have reinforced these findings, establishing TICASMART as a valuable option in the management of patients with acute coronary syndromes.

Conclusion

TICASMART 90MG is a crucial medication in the management of acute coronary syndrome, providing effective antiplatelet therapy that can significantly reduce the risk of serious cardiovascular events. Understanding its mechanism of action, pharmacological properties, and potential side effects is essential for healthcare providers prescribing this medication. Patients should be closely monitored for any adverse effects and educated on the importance of adherence to therapy for optimal outcomes. As with any medication, the benefits must be weighed against the risks, and treatment should be tailored to each individual patient based on their clinical profile.